Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00030173 | A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 45 | — | — | Oct 1, 2001 | Jun 1, 2003 | Jan 8, 2009 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Epothilone D (KOS-862) | DRUG | - |
Inclusion Criteria: 1. Diagnosis of histologically documented, advanced stage, primary or metastatic adult solid tumors that are refractory to standard therapy or for which no curative standard therapy exists. This includes but is not limited to cancers of the breast, ovary, head and neck, esophagu...